PRFX (PainReform Limited) Multiplikator Forward P/S
Flexible delegation of trials to external CRO contractors minimizes operational risks for PainReform Ltd. (PRFX). The forward P/S dynamics of the company confirm the asset's fundamental stability, where the 0.80 mark serves as a key metric. This reinforces its status as an M&A target through partnerships with clinics to implement PRF-110 and develop non-narcotic pain management methods that effectively address the issue of opioid addiction.
Rincian metrik komprehensif lan analitis PainReform Corp (PRFX)
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas PainReform Ltd.|PRFX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal PainReform Ltd.|PRFX - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku PainReform Corp|PRFX - Kewajiban jangka dawa|Utang jangka cendhak perusahaan PainReform|Likuiditas cepet painreform.com
- rincian asil keuangan lan kelipatan valuasi:
PRFX - Bathi pungkasan|Bathi sing dikarepake PainReform Ltd.|PRFX - Koefisien rega marang bathi|Prakiraan rega marang bathi PainReform Limited|PRFX - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PainReform Corp|PRFX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan PainReform|PRFX - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan painreform.com|PRFX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep PainReform Ltd.
- indikator volume dodolan lan pendapatan:
Analisis wiwitan perusahaan:PainReform PRFX
The development of the PRF-110 drug to combat opioid addiction transitions PainReform Ltd. (PRFX) into an expansion phase, where business valuation relies on future revenue streams. The projected P/S multiple correlates current market capitalization with expected sales, allowing investors to identify the presence of a market discount or systemic model risks without waiting for the publication of the next financial report.
Pesaing langsung
Rasio rega marang prakiraan pendapatan Haleon HLN|KVUE (Kenvue Inc) - Rega mangsa ngarep marang pendapatan|Verona Pharma Corp - Multiplikator Forward P/S|MENS - Multiplikator Forward P/S|LGND: Multiplikator Forward P/S|AMRX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Perrigo|Kapitalisasi marang prakiraan pendapatan ALVO (Alvotech S.A.)|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG (Galapagos Corp) - Rega forward marang dodolan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|mannkindcorp.com (MNKD) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan PCRX|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Theravance Corp (TBPH)|Rasio rega marang prakiraan pendapatan Aquestive Therapeutics|SCPH: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Tectonic Therapeutic, Inc. (TECX)|Multiplikator forward rega marang pendapatan Tonix Pharma TNXP|China SXT Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|EXOZ: Rasio rega marang prakiraan pendapatan|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|ENTX: Rasio rega marang pendapatan sing dikarepake|HYFT (MindWalk) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ABVC (ABVC BioPharma, Inc)|Multiplikator forward rega marang pendapatan CPIX (Cumberland Pharmaceuticals)|Rasio kapitalisasi marang dodolan sing dikarepake quantumbiopharma.com|Rasio rega marang prakiraan pendapatan FibroGen FGEN|TELO (Telomir Pharmaceuticals Inc) - Rega mangsa ngarep marang pendapatan|RANI - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan SNYR (Synergy CHC Corp)|RLYB: Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan LEXX (Lexaria Bioscience Corp.)|Multiplikator forward rega marang pendapatan PULM|Kapitalisasi marang prakiraan pendapatan PTHL (Pheton)|Rasio rega marang prakiraan pendapatan Aptorum Group Limited (APM)|LYRA: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S IBO (Impact BioMedical Inc)|Rega forward marang dodolan TNFA|cbdMD Corp - Multiplikator Forward P/S|CYTO - Multiplikator Forward P/S|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|OptiNose Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|Multiplikator forward rega marang pendapatan procapsgroup.com (PROC)|Multiplikator Forward P/S PTPI|Multiplikator Forward P/S Qilian International Holding Group (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan TFFP
